Sucampo Pharmaceuticals (NASDAQ:SCMP) Given News Impact Rating of 0.16
News headlines about Sucampo Pharmaceuticals (NASDAQ:SCMP) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Sucampo Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.12593112517 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Several equities analysts have commented on the stock. Maxim Group reiterated a “buy” rating and set a $23.00 price objective on shares of Sucampo Pharmaceuticals in a research report on Thursday, November 2nd. Mizuho downgraded shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $14.00 to $12.00 in a research note on Tuesday, October 3rd. B. Riley increased their target price on shares of Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, December 6th. Instinet assumed coverage on shares of Sucampo Pharmaceuticals in a research note on Tuesday, December 19th. They issued a “buy” rating and a $43.00 target price on the stock. Finally, Leerink Swann reissued a “market perform” rating and issued a $15.00 target price on shares of Sucampo Pharmaceuticals in a research note on Tuesday, January 2nd. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $19.50.
Sucampo Pharmaceuticals (NASDAQ SCMP) remained flat at $$17.95 during midday trading on Monday. 1,198,912 shares of the stock were exchanged, compared to its average volume of 3,800,000. The company has a current ratio of 5.11, a quick ratio of 4.46 and a debt-to-equity ratio of 7.37. The firm has a market cap of $837.13, a PE ratio of -5.36, a P/E/G ratio of 5.04 and a beta of 1.45. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $18.75.
In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $16.50, for a total value of $825,000.00. Following the sale, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.13% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Marea Informative and is owned by of Marea Informative. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.mareainformativa.com/2018/01/29/sucampo-pharmaceuticals-scmp-receives-daily-media-impact-score-of-0-16-updated-updated-updated.html.
Sucampo Pharmaceuticals Company Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.